GSK announced FDA’s approval of Blenrep in combination with bortezomib and dexamethasone (BVd) for the treatment of adults diagnosed with relapsed or refractory multiple myeloma who received a minimum ...
GlobalData on MSN
GSK’s Blenrep gains FDA approval for myeloma treatment
The approval is based on data from a Phase III trial evaluating patients who had received two or more previous treatments.
GSK’s Blenrep receives US FDA approval to treat relapsed/refractory multiple myeloma: London, UK Saturday, October 25, 2025, 11:00 Hrs [IST] GSK plc announced the US Food and Dr ...
London: GSK plc has received approval from the US Food and Drug Administration (FDA) for Blenrep (belantamab mafodotin-blmf) ...
Belantamab mafodotin, a BCMA-targeting ADC, is approved for relapsed/refractory multiple myeloma after two prior therapies, ...
GSK (GSK) announced the U.S. Food and Drug Administration (FDA) has approved Blenrep in combination with bortezomib and dexamethasone for the ...
(Alliance News) - GSK PLC said Thursday its drug Blenrep has been approved by the US Food & Drug Administration for the treatment of adults with relapsed or refractory multiple myeloma, the third most ...
Glovadalen, a novel D1 receptor positive allosteric modulator, is linked to improve OFF time in patients with Parkinson’s ...
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced landmark results demonstrating ...
Migraine Again on MSN
The Complete Guide to Migraine Relief: What’s New and What’s Still Tried-and-True
There are many effective acute and preventive migraine treatment options available today, including whole new medication ...
KEYTRUDA is indicated for the treatment of patients with resectable (tumors ≥4 cm or node positive) NSCLC in combination with platinum-containing chemotherapy as neoadjuvant treatment, and then ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback